SITERA Pharmaceuticals is a next-generation biotech company focused on a highly dynamic and largely untapped central platform in neuroscience: The Mitochondrial-ER Associated Membranes (MAMs). This platform serves as a key hub in the regulation of cellular metabolism, stress, and neuronal survival. By leveraging its proprietary technology platform, which combines cutting-edge chemical and biological expertise, SITERA design powerful, selective, and safe small molecule therapeutics that are capable of restoring impaired cellular functions in pathological contexts. The company is thus able to adress challenging central nervous system diseases and potentially provide clinical solutions and benefit for patients having rare and less rare neurodegenerative diseases with urgent and unmet medical needs.